Loading...

Quidel

DB:QL1
Snowflake Description

High growth potential with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
QL1
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
QL1 Share Price and Events
7 Day Returns
2.5%
DB:QL1
2.8%
DE Medical Equipment
1.6%
DE Market
1 Year Returns
-11.5%
DB:QL1
13.3%
DE Medical Equipment
-7.4%
DE Market
QL1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Quidel (QL1) 2.5% 5% -10.4% -11.5% 233.8% 215.8%
DE Medical Equipment 2.8% 5.1% 7.6% 13.3% 105.3% 245.6%
DE Market 1.6% 1.5% 3% -7.4% 14.7% 9.4%
1 Year Return vs Industry and Market
  • QL1 underperformed the Medical Equipment industry which returned 13.3% over the past year.
  • QL1 underperformed the Market in Germany which returned -7.4% over the past year.
Price Volatility
QL1
Industry
5yr Volatility vs Market

QL1 Value

 Is Quidel undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Quidel to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Quidel.

DB:QL1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:QL1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (7.71%))
0.936
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.936 * 5.96%)
5.8%

Discounted Cash Flow Calculation for DB:QL1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Quidel is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:QL1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.8%)
2019 144.00 Analyst x1 136.10
2020 159.00 Analyst x1 142.03
2021 4.00 Analyst x1 3.38
2022 3.10 Est @ -22.4% 2.48
2023 2.62 Est @ -15.61% 1.98
2024 2.33 Est @ -10.86% 1.66
2025 2.16 Est @ -7.53% 1.45
2026 2.05 Est @ -5.2% 1.30
2027 1.97 Est @ -3.58% 1.19
2028 1.93 Est @ -2.43% 1.10
Present value of next 10 years cash flows $292.67
DB:QL1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1.93 × (1 + 0.23%) ÷ (5.8% – 0.23%)
$34.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $34.61 ÷ (1 + 5.8%)10
$19.68
DB:QL1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $292.67 + $19.68
$312.35
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $312.35 / 39.82
$7.84
DB:QL1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:QL1 represents 0.85791x of NasdaqGS:QDEL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85791x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 7.84 x 0.85791
€6.73
Value per share (EUR) From above. €6.73
Current discount Discount to share price of €50.84
= -1 x (€50.84 - €6.73) / €6.73
-655.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Quidel is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Quidel's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Quidel's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:QL1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $1.66
NasdaqGS:QDEL Share Price ** NasdaqGS (2019-06-24) in USD $59.26
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 32x
Germany Market PE Ratio Median Figure of 425 Publicly-Listed Companies 20.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Quidel.

DB:QL1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:QDEL Share Price ÷ EPS (both in USD)

= 59.26 ÷ 1.66

35.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Quidel is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Quidel is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Quidel's expected growth come at a high price?
Raw Data
DB:QL1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 35.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
20.9%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.66x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

DB:QL1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 35.62x ÷ 20.9%

1.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Quidel is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Quidel's assets?
Raw Data
DB:QL1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $11.57
NasdaqGS:QDEL Share Price * NasdaqGS (2019-06-24) in USD $59.26
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.32x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.8x
DB:QL1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:QDEL Share Price ÷ Book Value per Share (both in USD)

= 59.26 ÷ 11.57

5.12x

* Primary Listing of Quidel.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Quidel is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Quidel's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Quidel has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

QL1 Future Performance

 How is Quidel expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Quidel expected to grow at an attractive rate?
  • Quidel's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Quidel's earnings growth is expected to exceed the Germany market average.
  • Quidel's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:QL1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:QL1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 20.9%
DB:QL1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 5.2%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.5%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:QL1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:QL1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 582 116 2
2020-12-31 557 191 99 6
2019-12-31 529 174 79 6
DB:QL1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 501 133 65
2018-12-31 522 136 74
2018-09-30 505 104 37
2018-06-30 438 90 20
2018-03-31 373 34 12
2017-12-31 278 28 -8
2017-09-30 216 33 -5
2017-06-30 214 38 0
2017-03-31 215 49 4
2016-12-31 192 12 -14
2016-09-30 189 11 -12
2016-06-30 187 11 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Quidel's earnings are expected to grow significantly at over 20% yearly.
  • Quidel's revenue is expected to grow by 5.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:QL1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Quidel Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:QL1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 2.65 2.65 2.65 1.00
2020-12-31 2.25 2.38 2.13 4.00
2019-12-31 1.85 1.92 1.76 4.00
DB:QL1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 1.66
2018-12-31 1.95
2018-09-30 1.00
2018-06-30 0.57
2018-03-31 0.34
2017-12-31 -0.24
2017-09-30 -0.15
2017-06-30 0.00
2017-03-31 0.12
2016-12-31 -0.42
2016-09-30 -0.37
2016-06-30 -0.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Quidel is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Quidel's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Quidel has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

QL1 Past Performance

  How has Quidel performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Quidel's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Quidel has delivered over 20% year on year earnings growth in the past 5 years.
  • Quidel's 1-year earnings growth exceeds its 5-year average (465.7% vs 71.8%)
  • Quidel's earnings growth has exceeded the DE Medical Equipment industry average in the past year (465.7% vs 3.2%).
Earnings and Revenue History
Quidel's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Quidel Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:QL1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 501.11 65.07 156.75 52.96
2018-12-31 522.29 74.18 152.82 51.65
2018-09-30 504.59 36.62 149.60 49.68
2018-06-30 438.08 20.27 132.64 44.05
2018-03-31 373.19 11.50 114.19 38.39
2017-12-31 277.74 -8.17 96.44 33.64
2017-09-30 215.66 -5.03 81.81 30.48
2017-06-30 214.11 -0.07 79.85 31.81
2017-03-31 214.97 3.93 78.46 33.84
2016-12-31 191.60 -13.81 76.79 38.67
2016-09-30 189.11 -12.24 75.81 41.10
2016-06-30 186.58 -12.43 75.60 40.72
2016-03-31 182.65 -13.52 75.35 40.17
2015-12-31 194.03 -6.08 77.46 35.51
2015-09-30 205.67 1.41 76.23 34.77
2015-06-30 200.90 -3.59 75.76 38.46
2015-03-31 197.19 -1.57 73.38 37.18
2014-12-31 184.16 -7.07 68.89 37.91
2014-09-30 168.58 -13.05 65.94 40.00
2014-06-30 160.07 -11.63 62.57 35.33
2014-03-31 158.29 -6.46 59.59 35.44
2013-12-31 177.33 7.37 61.33 34.19
2013-09-30 179.17 14.95 56.15 30.18
2013-06-30 178.62 18.62 54.52 27.84
2013-03-31 179.78 17.23 54.47 26.74
2012-12-31 155.74 4.97 50.12 27.72
2012-09-30 140.21 -2.80 50.22 25.56
2012-06-30 140.32 -3.22 49.37 26.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Quidel has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Quidel used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Quidel has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Quidel's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Quidel has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

QL1 Health

 How is Quidel's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Quidel's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Quidel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Quidel's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Quidel's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Quidel Company Filings, last reported 2 months ago.

DB:QL1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 460.70 88.07 56.94
2018-12-31 425.58 107.57 43.70
2018-09-30 388.45 137.07 38.69
2018-06-30 368.91 134.38 38.68
2018-03-31 330.65 226.88 101.81
2017-12-31 227.10 397.45 36.09
2017-09-30 218.88 148.47 172.99
2017-06-30 212.59 147.08 175.05
2017-03-31 220.12 145.71 197.49
2016-12-31 200.63 144.34 169.51
2016-09-30 196.75 142.99 153.36
2016-06-30 193.04 141.64 155.57
2016-03-31 198.40 140.31 153.45
2015-12-31 218.68 143.30 191.47
2015-09-30 219.41 141.95 182.56
2015-06-30 230.11 140.61 204.74
2015-03-31 251.45 139.28 229.43
2014-12-31 245.01 137.96 200.90
2014-09-30 217.37 0.00 17.37
2014-06-30 219.85 0.00 18.08
2014-03-31 225.01 0.00 25.16
2013-12-31 223.78 0.00 8.39
2013-09-30 217.66 0.00 10.25
2013-06-30 219.49 0.00 21.95
2013-03-31 218.42 0.00 44.38
2012-12-31 199.78 5.00 14.86
2012-09-30 186.67 19.00 17.84
2012-06-30 183.76 19.00 19.88
  • Quidel's level of debt (20.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.4% vs 20.1% today).
  • Debt is well covered by operating cash flow (143.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.3x coverage).
X
Financial health checks
We assess Quidel's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Quidel has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

QL1 Dividends

 What is Quidel's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Quidel dividends.
If you bought €2,000 of Quidel shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Quidel's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Quidel's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:QL1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:QL1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Quidel has not reported any payouts.
  • Unable to verify if Quidel's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Quidel's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Quidel has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Quidel's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Quidel afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Quidel has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

QL1 Management

 What is the CEO of Quidel's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doug Bryant
COMPENSATION $3,421,307
AGE 60
TENURE AS CEO 10.3 years
CEO Bio

Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice President of Luminex Corporation from July 16, 2007 to February 1, 2009. He oversaw all elements of Luminex's operations, including worldwide sales and marketing, its molecular diagnostics subsidiary, Luminex Molecular Diagnostics, the Luminex Bioscience Group, as well as its manufacturing and worldwide service and support operations. He has over 23 years of industry experience in sales and marketing, product development, manufacturing and service and support in both the life sciences and diagnostics markets. Prior to Luminex, he served as Vice President, Global Commercial Operations of Abbott Laboratories since 2003. From 1983 to 2007, Mr. Bryant held various worldwide commercial operations positions with Abbott Laboratories, a broad-based healthcare company, including, among others: Vice President of Abbott Vascular for Asia/Japan and Vice President of Abbott Diagnostics Global Commercial Operations. He served as Vice President, Diagnostics Commercial Operations, Europe, Africa and Middle East divisions of Abbott Laboratories from 2002 to 2003 and served as its Corporate Officer since 1998. Mr. Bryant served as Vice President of Diagnostics Operations for Asia and Pacific at Abbott Laboratories from 1998 to 2002 and served as its Commercial Director, Asia and Pacific, Diagnostic Products since 1998. Mr. Bryant has been a Director of Quidel Corp. since February 2, 2009. Mr. Bryant has a Bachelor of Arts in Economics from the University of California, Davis.

CEO Compensation
  • Doug's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Doug's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Quidel management team in years:

5.1
Average Tenure
55
Average Age
  • The average tenure for the Quidel management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Doug Bryant

TITLE
President
COMPENSATION
$3M
AGE
60
TENURE
10.3 yrs

Randy Steward

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
64
TENURE
7.7 yrs

Robert Bujarski

TITLE
Senior VP of Business Development & General Counsel
COMPENSATION
$1M
AGE
50
TENURE
13.9 yrs

Werner Kroll

TITLE
Senior Vice President of Research & Development
COMPENSATION
$2M
AGE
61
TENURE
5.1 yrs

Michael Abney

TITLE
Senior Vice President of Distribution
COMPENSATION
$1M
AGE
54
TENURE
4.4 yrs

Ruben Argueta

TITLE
Director of Investor Relations

Ratan Borkar

TITLE
Senior Vice President of International Commercial Operations
AGE
44
TENURE
1.7 yrs

Ed Russell

TITLE
Senior Vice President of Global Commercial Operations
COMPENSATION
$1M
AGE
50
TENURE
3.7 yrs

Karen Gibson

TITLE
Senior Vice President of Information Systems & Business Transformation
AGE
56
Board of Directors Tenure

Average tenure and age of the Quidel board of directors in years:

4.2
Average Tenure
64
Average Age
  • The tenure for the Quidel board of directors is about average.
Board of Directors

Ken Buechler

TITLE
Chairman
COMPENSATION
$226K
AGE
64
TENURE
3.8 yrs

Doug Bryant

TITLE
President
COMPENSATION
$3M
AGE
60
TENURE
10.3 yrs

Ken Widder

TITLE
Independent Director
COMPENSATION
$162K
AGE
65
TENURE
4.6 yrs

Charlie Slacik

TITLE
Independent Director
COMPENSATION
$161K
AGE
64
TENURE
3.6 yrs

Mary Polan

TITLE
Independent Director
COMPENSATION
$152K
AGE
74
TENURE
26.3 yrs

Jack Schuler

TITLE
Independent Director
COMPENSATION
$152K
AGE
78
TENURE
13.3 yrs

Matthew Strobeck

TITLE
Director
COMPENSATION
$140K
AGE
45
TENURE
1.2 yrs

Ed Michael

TITLE
Director
COMPENSATION
$58K
AGE
61
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • Quidel individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. May 19 Sell Charles Slacik Individual 20. May 19 20. May 19 -1,000 €49.40 €-49,401
21. May 19 Buy Schuler Family Foundation, Endowment Arm Company 10. May 19 13. May 19 117,671 €53.65 €6,173,102
22. Feb 19 Sell Mary Polan Individual 20. Feb 19 20. Feb 19 -14,449 €61.76 €-892,402
20. Feb 19 Sell Mary Polan Individual 15. Feb 19 15. Feb 19 -13,772 €57.76 €-795,537
07. Dec 18 Sell Randall Steward Individual 03. Dec 18 03. Dec 18 -15,000 €54.17 €-812,580
31. Aug 18 Sell Mary Polan Individual 28. Aug 18 28. Aug 18 -2,358 €60.42 €-142,481
28. Aug 18 Sell Mary Polan Individual 23. Aug 18 27. Aug 18 -16,002 €60.02 €-960,093
15. Aug 18 Sell Charles Slacik Individual 10. Aug 18 10. Aug 18 -1,000 €59.81 €-59,810
X
Management checks
We assess Quidel's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Quidel has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

QL1 News

Simply Wall St News

QL1 Company Info

Description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

Details
Name: Quidel Corporation
QL1
Exchange: DB
Founded: 1979
$2,070,186,591
39,817,679
Website: http://www.quidel.com
Address: Quidel Corporation
12544 High Bluff Drive,
Suite 200,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS QDEL Common Stock Nasdaq Global Select US USD 18. Oct 1983
OTCBB QBSW Common Stock OTC Bulletin Board US USD 18. Oct 1983
DB QL1 Common Stock Deutsche Boerse AG DE EUR 18. Oct 1983
Number of employees
Current staff
Staff numbers
1,224
Quidel employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 20:52
End of day share price update: 2019/06/24 00:00
Last estimates confirmation: 2019/06/20
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.